To help diagnose the cause of hemolytic anemia as caused by autoimmune disease or induced by drugs; to investigate a transfusion reaction; to diagnose hemolytic disease of the newborn. The direct antiglobulin test (DAT) is used primarily to help determine if the cause of hemolytic anemia, a condition in which red blood cells (RBCs) are being destroyed more quickly than they can be replaced, is due to antibodies attached to RBCs. This may occur in autoimmune-related hemolytic anemias, which are caused by a person producing antibodies against their own RBC antigens (autoantibodies). Examples of this include autoimmune disorders such as systemic lupus erythematosus, malignant diseases such as lymphoma and chronic lymphocytic leukemia, and infections such as mycoplasma pneumonia and mononucleosis. It can also occur in some people with the use of certain medications, such as penicillin.
A DAT may be used to help diagnose hemolytic disease of the newborn (HDN) due to an incompatibility between the blood types of a mother and baby. When a baby is born, the mother may be exposed to the foreign antigens on the baby’s RBCs and may produce antibodies directed against the baby’s RBC antigens. This may occur when an Rh-positive baby is born to an Rh-negative mother. Formerly, antibodies to the Rh antigen were the most common cause of hemolytic disease of the newborn, but this condition is now rare due to preventive treatments given to the mother during and after each pregnancy. The most common cause of hemolytic disease of the newborn nowadays is an ABO incompatibility between a Group O mother and her baby. This type of fetal-maternal incompatibility is generally mild.
RBC Antibody Screen; Blood Typing; Red Blood Cell Antibody Identification
Global & National Quality Accreditations – CAP (USA) and NABL , Govt. of India.
Guaranteed error free diagnosis.
Bar Coded and automated process. No room for manual errors.
Specific normal range for Indian population built from 33 years of experience.
Sample collection from home/office.
Metropolis: Experience + Expertise
Over the past 3 decades we have earned the respect of doctors and patients. Today we conduct over 30 million tests annually with accuracy each year. Our repertoire extends over 4500 tests and over 100 different technologies. Our customer care is available round the clock for any queries that you may have.
Save tax on the Preventive health check-ups up to Rs. 5000, under section 80D of Income Tax Act, 1961
We are Metropolis - Your Pathology Specialist
Metropolis is one of the leading diagnostics companies in India, by revenue, as of March 31, 2018 (Source: Frost & Sullivan). With operations across India, Africa, South Asia and Middle East.
Our globally accredited clinical laboratories deliver accurate and timely test results. We offer a comprehensive range of clinical laboratory tests and profiles which are used in prediction, early detection, diagnostic screening, confirmation and monitoring of diseases.
Delivering diagnostic services since 1980
Network of 100+ clinical labs & 1100+ patient touch points
Qualified team of phlebotomists for Home collection services
Certified NABL and CAP accredited labs
Wide range of 4000+ tests & profiles
Convenience of home collection service
Metropolis Healthcare Limited is proposing subject to applicable statutory or regulatory requirements, receipt of requisite approvals, market conditions and other considerations to undertake an initial public offering of its equity shares and has filed a draft red herring prospectus dated September 27, 2018 (“DRHP”) with the Securities and Exchange Board of India (“SEBI”). The DRHP is available on the website of the SEBI at www.sebi.gov.in, BSE Limited at www.bseindia.com, National Stock Exchange of India Limited at www.nseindia.com and the websites of Book Running Lead Managers at www.jmfl.com, www.credit-suisse.com, www.investmentbank.kotak.com, www.hdfcbank.com and www.goldmansachs.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to same, please refer to the DRHP including the section “Risk Factors” of the DRHP. Potential investors should not rely on the DRHP filed with the SEBI for making any investment decision.